Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 20 Lung Neoplasms 9 NSCLC 3 Brain Neoplasms 3 Neoplasms 2 Squamous Cell Carcinoma of Lung 1 Non-squamous Non-small Cell Lung Cancer 1 Non-small Cell Lung Cancer Metastatic 1 Non-Small-Cell Lung 1 Neuroma, Acoustic 1 Neurofibromatosis 2 1 Neoplasms, Second Primary 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 Esophageal Neoplasms 1 Drug-Related Side Effects and Adverse Reactions 1 Bronchial Neoplasms 1 Breast Neoplasms 1 Adenocarcinoma of Lung 1

Interventions

Pemetrexed 4 pembrolizumab 3 Carboplatin 3 Vinorelbine 2 Gemcitabine 2 vistusertib 1 vandetanib 1 spartalizumab 1 sotorasib 1 sintilimab 1 olaparib 1 icotinib 1 durvalumab 1 dacomitinib 1 capivasertib 1 aumolertinib 1 Radiosurgery 1 Platinum 1 MLN 8237 1 Injections 1 Immune Checkpoint Inhibitors 1 Gefitinib 1 GC Temporary Stopping 1 Erlotinib Hydrochloride 1 Drug Therapy 1 Cisplatin 1 Bevacizumab 1 AZD4547 1 AZD 8931 1 AZD 6244 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Non-small Cell Lung Cancer Metastatic × icotinib × Clear all

NCT06517953 2024-07-25

IcomBine

Sun Yat-sen University

Phase 2 Recruiting

Non-small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡